Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIG07
- Development stage
- Preclinical
- Lead developer
- AIGEN Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AIG07 is a preclinical-stage small molecule inhibitor of Ubiquitin-specific protease 1 (USP1), developed by AIGEN Sciences. USP1 is a deubiquitinating enzyme that plays a critical role in DNA damage response (DDR) pathways, particularly in the repair of DNA interstrand crosslinks and translesion synthesis. By inhibiting USP1, AIG07 aims to exploit synthetic lethality in tumors with homologous recombination deficiency (HRD), such as BRCA1-deficient solid cancers. The drug is currently in the candidate selection phase of preclinical development.
- Other names
- AIG07AIG-07AIG 07
02
Targets
USP1 (Ubiquitin-specific protease 1)
Beyond the preview
Go deeper on AIG07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIG07.